Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Hyperkalemia (HK) is the most common electrolyte disturbance in advanced chronic kidney disease (CKD).
• HK increases the risk of fatal arrhythmias and negatively impacts CKD patient prognosis and quality of life.
• Renin-angiotensin-aldosterone system inhibitors (RAASIs), crucial for cardio-renal protection, can elevate serum potassium (sK), complicating their use, especially with coexisting heart failure and diabetes.

Purpose of the Study:

• To review current evidence on managing chronic hyperkalemia in patients with cardio-renal conditions.
• To highlight the unmet need for effective long-term HK management strategies.
• To discuss the potential of novel potassium binders in transforming treatment landscapes.

Main Methods:

• Literature review of current evidence on chronic HK treatment in cardio-renal patients.
• Analysis of the limitations of existing HK management strategies.
• Discussion of the role of RAASIs and their impact on sK levels.

Main Results:

• Current strategies (diet, diuretics, older binders) for chronic HK are often unsatisfactory due to limited efficacy and poor tolerability.
• HK recurrence frequently leads to RAASI down-titration or withdrawal, compromising cardio-renal protection.
• There is a significant unmet need for effective, well-tolerated, long-term therapies for HK management in CKD patients.

Conclusions:

• Effective long-term management of chronic hyperkalemia in CKD patients remains a significant clinical challenge.
• Novel potassium binders show promise for improving the treatment of HK, potentially allowing continued use of beneficial RAASIs.
• Further research and development of new therapeutic options are crucial for optimizing outcomes in this vulnerable patient population.